Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
RESEARCH TOOLSreports
Holding EYPT?
Track your performance easily
EYPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.86 - $30.99
Previous Close$8.96
Volume2.64M
Average Volume (3M)760.47K
Market Cap
$569.90M
Enterprise Value$396.72M
Total Cash (Recent Filing)$253.79M
Total Debt (Recent Filing)$21.92M
Price to Earnings (P/E)―
Beta3.11
Next Earnings
Feb 27, 2025EPS Estimate
-$0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding68,251,031
10 Day Avg. Volume853,984
30 Day Avg. Volume760,471
Standard Deviation0.45
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.80
Price to Sales (P/S)13.75
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.46
Enterprise Value/Gross Profit9.59
Enterprise Value/Ebitda-3.93
Forecast
1Y Price Target
$26.86Price Target Upside221.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EyePoint Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressEYPT made significant progress as the first patient was dosed in the LUGANO Phase III wet AMD trial.
Market PerformanceEYPT shares are up more than 30% following the release of positive interim clinical data from its Phase 2 VERONA trial investigating DURAVYU in diabetic macular edema.
Treatment Efficacy And SafetyDuravyu demonstrated an early and sustained improvement in both BCVA and CST, with no DURAVYU associated ocular serious adverse events reported, highlighting its favorable safety profile.
Bears Say
Clinical ChallengesThe path forward for CLS-AX is seen as potentially challenging both clinically and commercially, reinforcing the competitive edge for EYPT.
Study DataData for Duravyu in the Phase 2 PAVIA study in NPDR are worse than feared.
Trial ResultsFollowing disappointing results for Duravyu in the Phase 2 PAVIA study in diabetic retinopathy and discontinuation of further development in DR, the Phase 2 VERONA trial in diabetic macular edema comparing Duravyu to one dose of Eylea is fully enrolled.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
EYPT FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $5.86 and its highest was $30.99 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is Feb 27, 2025 which is in 97 days.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on Nov 07, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.546 by $0.006.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -$0.5.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 68,251,030 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.546. Following the earnings report the stock price went down -4.056%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Among the largest hedge funds holding EyePoint Pharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds EyePoint Pharmaceuticals Inc’s shares valued at 8M.
---
EyePoint Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.86 (221.68% Upside)
$26.86 (221.68% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 77%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 321.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.5%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
36.43%
12-Months-Change
Fundamentals
Return on Equity
-74.68%
Trailing 12-Months
Asset Growth
88.02%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
---
EYPT Earnings Call
Q4 2024
0:00 / 0:00
---
EYPT Stock 12 Month Forecast
Average Price Target
$26.86
▲(221.68% Upside)
Technical Analysis
Best Analysts Covering EYPT
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
+16.55%
reiterated a buy rating 12 days ago
Copying Colleen M. Kusy's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +16.55% per trade.
---